Should All Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease Receive an SGLT2 Inhibitor?
出版信息
Can J Hosp Pharm. 2018 Jul-Aug;71(4):282-285. Epub 2018 Aug 28.
Abstract
摘要
相似文献
1
Should All Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease Receive an SGLT2 Inhibitor?所有2型糖尿病合并心血管疾病患者都应使用钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂吗？
Can J Hosp Pharm. 2018 Jul-Aug;71(4):282-285. Epub 2018 Aug 28.
2
Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US.美国糖尿病患者中钠-葡萄糖共转运蛋白 2 抑制剂使用与种族/民族、性别和社会经济地位的关联。
JAMA Netw Open. 2021 Apr 1;4(4):e216139. doi: 10.1001/jamanetworkopen.2021.6139.
3
Cardiovascular Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Adults With Type 2 Diabetes.钠-葡萄糖共转运蛋白 2 抑制剂对 2 型糖尿病成人的心血管影响。
Can J Diabetes. 2020 Feb;44(1):61-67. doi: 10.1016/j.jcjd.2019.09.004. Epub 2019 Sep 24.
4
Prescribing patterns and factors associated with sodium-glucose cotransporter-2 inhibitor prescribing in patients with diabetes mellitus and atherosclerotic cardiovascular disease.糖尿病合并动脉粥样硬化性心血管疾病患者中钠-葡萄糖共转运蛋白 2 抑制剂的处方模式及相关因素。
CMAJ Open. 2023 Jun 13;11(3):E494-E503. doi: 10.9778/cmajo.20220039. Print 2023 May-Jun.
5
Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial.在 2 型糖尿病中，与或不与钠-葡萄糖共转运蛋白 2 抑制联合使用 efpeglenatide 的临床结局和：AMPLITUDE-O 试验的探索性分析。
Circulation. 2022 Feb 22;145(8):565-574. doi: 10.1161/CIRCULATIONAHA.121.057934. Epub 2021 Nov 14.
6
Initiation of SGLT2 inhibitors and GLP-1 receptor agonists according to level of frailty in people with type 2 diabetes and cardiovascular disease in Denmark: a cross-sectional, nationwide study.根据丹麦 2 型糖尿病和心血管疾病患者虚弱程度启动 SGLT2 抑制剂和 GLP-1 受体激动剂：一项横断面、全国性研究。
Lancet Healthy Longev. 2023 Oct;4(10):e552-e560. doi: 10.1016/S2666-7568(23)00164-2. Epub 2023 Sep 18.
7
Association between SGLT2 Inhibitors and Cardiac Rehabilitation Outcomes in Patients with Cardiovascular Disease and Type 2 Diabetes Mellitus.心血管疾病合并2型糖尿病患者中，钠-葡萄糖协同转运蛋白2抑制剂与心脏康复结局之间的关联
J Clin Med. 2022 Oct 9;11(19):5956. doi: 10.3390/jcm11195956.
8
GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes.GLP-1 受体激动剂联合或不联合 SGLT2 抑制剂治疗 2 型糖尿病患者。
J Am Coll Cardiol. 2023 Aug 8;82(6):517-525. doi: 10.1016/j.jacc.2023.05.048.
9
Can we go beyond surrogates?我们能否超越代理人？
J Diabetes. 2017 Nov;9(11):976-977. doi: 10.1111/1753-0407.12583.
10
Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.SGLT2 抑制剂在心血管疾病和肾功能障碍中的保护作用机制。
Curr Top Med Chem. 2019;19(20):1818-1849. doi: 10.2174/1568026619666190828161409.
本文引用的文献
1
Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease.钠-葡萄糖协同转运蛋白2抑制剂达格列净对2型糖尿病合并3b-4期慢性肾脏病患者的影响。
Nephrol Dial Transplant. 2018 Jul 1;33(7):1280. doi: 10.1093/ndt/gfy135.
2
Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis.钠-葡萄糖共转运蛋白 2 抑制剂、胰高血糖素样肽 1 受体激动剂和二肽基肽酶 4 抑制剂与 2 型糖尿病患者全因死亡率的关联：系统评价和荟萃分析。
JAMA. 2018 Apr 17;319(15):1580-1591. doi: 10.1001/jama.2018.3024.
3
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.卡格列净与 2 型糖尿病的心血管和肾脏事件。
N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12.
4
Effect of Glucagon-like Peptide-1 Receptor Agonists on All-cause Mortality and Cardiovascular Outcomes: A Meta-analysis.胰高血糖素样肽-1受体激动剂对全因死亡率和心血管结局的影响：一项荟萃分析。
Curr Diabetes Rev. 2018;14(3):273-279. doi: 10.2174/1573399813666170414101450.
5
Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.钠-葡萄糖协同转运蛋白2抑制剂在2型糖尿病患者中的利弊：一项系统评价和荟萃分析
PLoS One. 2016 Nov 11;11(11):e0166125. doi: 10.1371/journal.pone.0166125. eCollection 2016.
6
DPP-4 Inhibitors: The Seinfeld of Oral Antihyperglycemics.二肽基肽酶-4抑制剂：口服降糖药中的《宋飞正传》
Can J Hosp Pharm. 2016 May-Jun;69(3):253-4. doi: 10.4212/cjhp.v69i3.1564. Epub 2016 Jun 30.
7
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.恩格列净与 2 型糖尿病患者的肾脏疾病进展。
N Engl J Med. 2016 Jul 28;375(4):323-34. doi: 10.1056/NEJMoa1515920. Epub 2016 Jun 14.
8
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.利拉鲁肽与2型糖尿病患者的心血管结局
N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.
9
Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns-NHANES 2007-2012.了解 T2DM 患者中的 CKD：患病率、时间趋势和治疗模式-NHANES 2007-2012。
BMJ Open Diabetes Res Care. 2016 Apr 11;4(1):e000154. doi: 10.1136/bmjdrc-2015-000154. eCollection 2016.
10
SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis.用于治疗2型糖尿病患者的SGLT-2受体抑制剂：一项系统评价和网状Meta分析
BMJ Open. 2016 Feb 24;6(2):e009417. doi: 10.1136/bmjopen-2015-009417.
Zotero 插件